If you have been reading about gastric juice protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
== History == The term "fine chemicals" was in use as early as 1908. The emergence of the fine chemical industry as a distinct entity dates to the late 1970s, when the overwhelming success of the histamine H2 receptor antagonists Tagamet (cimetidine) and Zantac (ranitidine hydrochloride) created a strong demand for advanced organic chemicals used in their manufacture. As the in-house production capacities of the originators, the pharmaceutical companies Smith, Kline, & French and Glaxo, could not keep pace with the rapidly increasing requirements, both companies (now merged as GlaxoSmithKline) outsourced part of the manufacturing to chemical companies experienced in producing relatively sophisticated organic molecules. Lonza, Switzerland, which had already had supplied an early intermediate, methyl acetoacetate, during drug development, soon became the main supplier of more and more advanced precursors. The signature of a first, simple supply contract is generally acknowledged as the historical document marking the beginning of the fine chemical industry.
Pelage Pharmaceuticals presented on suvomipic at the American Academy of Dermatology (AAD) Annual Meeting 2026 in March 2026, including disclosing some new phase 2a trial data, but did not provide the open-label extension data at this event. Phase 3 trials of suvomipic for alopecia are being planned for 2026. It has been estimated that if suvomipic is successful in clinical trials and passes regulatory scrutiny, the drug could be approved for the treatment of hair loss sometime between 2027 and 2029 at the earliest. Suvomipic is currently Pelage Pharmaceuticals's only official drug candidate. However, the company is also investigating reactivation of dormant stem cells for treatment of other medical conditions. Pelage Pharmaceuticals had raised more than $30 million by August 2025, with investment being led by Google Ventures of Alphabet. In October 2025, it was announced that the company had raised $120 million. In 2019, Pelage Pharmaceuticals had reached an agreement that granted Allergan (now AbbVie) an option to acquire the startup company, but this deal was terminated in 2020. Suvomipic may also have applications in the treatment of other forms of hair loss besides androgenic alopecia. In October 2025, Time magazine named suvomipic one of the best inventions of 2025. However, the magazine also disclosed, via communication with Pelage Pharmaceuticals, that suvomipic may not be effective in the end stages of balding if the hair follicle is "scarred".
Feline cutaneous asthenia is a rare inheritable skin disease of cats characterised by abnormal elasticity, stretching, and improper healing of the skin. Pendulous wing-like folds of skin form on the cat's back, shoulders and haunches. Even stroking the cat can cause the skin to stretch and tear. A recessive autosomal (non-sex linked) form of feline cutaneous asthenia has been identified in Siamese cats and related breeds. In the homozygous state, it is apparently lethal. Feline cutaneous asthenia is similar to the Ehlers–Danlos syndrome of humans. Cats with cutaneous asthenia cannot be grasped by the scruff, as this may tear away. Cats may also have slipping joints, as in human Ehlers-Danlos syndrome. Dietary supplements may be needed to promote skin healing and regrowth.
Sources: en.wikipedia.org
In 2008, Cephalon, the manufacturer of Provigil, pleaded guilty to a federal criminal charge related to its promotion of off-label uses of Provigil and two other drugs, paying $425 million in fines and settlements.
=== 26 February === Food aid was halted due to continued attacks on the Zamzam camp. Russia called on the UN to support the Sudanese government's peace efforts and warned against the parallel RSF government that could halt efforts to support stability in Sudan.
The second edition in the Retro series was a collection of "Making of" features, most of which had run previously in the main magazine. These features usually contained interviews with the makers of classic video games talking about the process involved in their title's creation. "Edge presents Equip: PlayStation 2 edition" "Edge presents Equip: GameCube edition" "Edge presents Equip: PC edition" "Edge presents Equip: Xbox edition"
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.